Key result
Doxorubicin, but not idarubicin, caused statistically significant changes in lipid bilayer fluidity, protein conformation, and microviscosity in erythrocytes from acute myeloid leukaemia patients.
Why the study?
Does doxorubicin or idarubicin alter the biophysical properties of erythrocytes from acute myeloid leukaemia patients?
Does doxorubicin or idarubicin alter the biophysical properties of erythrocytes from acute myeloid leukaemia patients?
Idarubicin appears to be less toxic to erythrocytes than doxorubicin in acute myeloid leukemia patients.
May suggest lower erythrocyte membrane toxicity with idarubicin than doxorubicin in AML; hypothesis-generating and requires clinical validation before influencing therapy.
Doxorubicin (DOX) and idarubicin (IDA) are anthracycline antibiotics, widely used in human cancer treatment. The present study addressed the effects of these two drugs on lipid bilayer fluidity, protein conformation and microviscosity in erythrocytes from acute myeloid leukaemia patients, using electron spin resonance (ESR) spectroscopy and fluorescence measurements. Only DOX caused statistically significant changes in the parameters examined. Within 30 min of drug injection, changes were observed in the fluidity of the hydrophobic parts of the lipid bilayer and erythrocyte membrane protein conformation. These changes persisted for up to 24h. Analysis of the EPR Tempamine spectrum also showed that the microviscosity of the erythrocyte interior increased during the early stages of the drug effect. Idarubicin, in contrast, caused no identifiable change in any of the parameters studied and therefore seems to be safe for erythrocytes. We conclude that IDA is markedly less toxic than DOX to erythrocytes from acute myeloid leukaemia patients.
No takes yet. Share an insight, caveat, or question.
Marczak et al. (2005) studied Acute myeloid leukaemia. Doxorubicin and idarubicin vs. Each other was evaluated on Lipid bilayer fluidity, protein conformation and microviscosity in erythrocytes. Doxorubicin, but not idarubicin, caused statistically significant changes in lipid bilayer fluidity, protein conformation, and microviscosity in erythrocytes from acute myeloid leukaemia patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: